Launching a product is always an intense, pivotal moment, but in a fast moving era of scientific advances and regulatory change, it has become an even more critical enterprise.
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.